GO:0140677 molecular function activator activity: Mechanism, Genes and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0140677 molecular function activator activity describes a regulator that increases the activity of a target protein through non-covalent binding without covalently modifying it.
• Activators work by diverse mechanisms including allosteric conformational change, scaffold stabilization, and recruitment of cofactors, as illustrated by transcriptional activators and proteasome activators [2,4].
• Small-molecule activators such as sirtuin activators and hesperetin demonstrate the pharmacological relevance of this function [3,5].
• Engineered viral proteins can activate STAT5 to prevent T cell suppression, showing therapeutic potential of activator engineering.
• Dysregulation of activator activity is linked to diseases including diabetic cardiomyopathy, glomerular proteinuria, and cancer [1,7].
• CRISPR-based knockout, knock-in, and overexpression models are essential to dissect the causal role of molecular function activators [2,8].
Description
Molecular function activator activity (GO:0140677) is a regulatory molecular function in which a protein or small molecule binds non-covalently to a target and increases its activity without covalently modifying it. This term captures a fundamental mode of biological regulation that is distinct from enzymatic catalysis or covalent modification. Activators are critical for fine-tuning cellular responses, from transcription and proteolysis to metabolic control and immune signaling [2,4,8]. Understanding activator mechanisms is essential for both basic biology and therapeutic development, as exemplified by sirtuin activators and engineered viral proteins that boost immune cell function [3,8]. In this article, we synthesize authoritative QuickGO annotations and verified PubMed literature to provide a research-grade overview of GO:0140677, its mechanisms, key genes, disease links, and experimental approaches.
molecular function activator activity At A Glance
| GO ID | GO:0140677 |
|---|---|
| GO term | molecular function activator activity |
| Ontology | molecular_function |
| Synonym | none |
| Major function | Non-covalent activation of a target protein's activity |
| Parent term | molecular function regulator |
| Mechanism | Allosteric or scaffold-mediated increase in target activity |
| Examples | Transcriptional activators, proteasome activators, sirtuin activators |
What Is GO:0140677?
According to the Gene Ontology, molecular function activator activity (GO:0140677) is a molecular function regulator that activates or increases the activity of its target via non-covalent binding that does not result in covalent modification to the target. In other words, the activator physically associates with its target protein, often through allosteric or scaffolding interactions, and enhances the target's functional output without chemically altering it.
Why Is molecular function activator activity Important in Cell Biology?
Molecular function activator activity is central to virtually all cellular processes because it provides a reversible and tunable way to boost protein function in response to signals. Unlike covalent modifications, non-covalent activation allows rapid and dynamic control of enzyme, transcription factor, and signaling protein activities [2,4]. This regulatory mode is exploited by natural systems and by therapeutics: small-molecule activators can enhance sirtuin activity to combat aging-related diseases, and engineered proteins can activate STAT5 to enhance T cell persistence in cancer immunotherapy [3,5,8]. Consequently, understanding activator mechanisms is vital for drug discovery and for interpreting disease-associated mutations.
• Enables rapid, reversible control of protein activity without covalent modification.
• Underlies transcriptional activation in human cells, a key step in gene expression.
• Regulates proteasome activity, impacting protein degradation and cellular homeostasis.
• Sirtuin activators are pursued for metabolic and aging-related therapies.
• Small-molecule activators like hesperetin can delay senescence and rejuvenate skin.
• Engineered viral protein activators of STAT5 enhance T cell function in immunotherapy.
• Dysregulated activator activity contributes to diabetic cardiomyopathy and kidney disease [1,7].
• CRISPR screens can identify novel activators and their targets.
What Happens During molecular function activator activity?
Target recognition and binding
In simple terms: The activator first finds and sticks to its target protein.
The process begins when the activator protein or small molecule recognizes and binds non-covalently to its target. This binding is specific and often involves allosteric sites or protein-protein interaction domains. For example, transcriptional activators bind to promoter-bound factors or coactivators to stimulate transcription. Proteasome activators bind to the 20S proteasome and induce conformational changes that open the substrate channel.
Conformational change and activity enhancement
In simple terms: Binding causes the target to change shape and become more active.
Upon binding, the activator induces a conformational change in the target that increases its catalytic or functional activity. This can involve allosteric activation, stabilization of an active conformation, or recruitment of additional cofactors. For instance, sirtuin activators like resveratrol bind to SIRT1 and enhance its deacetylase activity by lowering the Km for substrates. Similarly, hesperetin activates CISD2, leading to reduced senescence in keratinocytes.
Downstream signaling and cellular responses
In simple terms: The activated target then triggers a cascade of cellular effects.
Once activated, the target protein propagates signals or performs its function more efficiently. This can lead to changes in gene expression, protein degradation, metabolic flux, or immune cell activity. For example, an engineered viral protein activates STAT5, which then promotes T cell survival and prevents suppression. In diabetic cardiomyopathy, METTL3 activation is essential for exercise benefits, linking activator function to metabolic health.
Regulation and termination
In simple terms: The activation is controlled and can be turned off when needed.
Activator activity is tightly regulated to avoid excessive signaling. This can occur through degradation of the activator, competition with inhibitors, or post-translational modifications that disrupt binding. For instance, amiloride reduces urokinase/plasminogen-driven complement activation in glomerular proteinuria, illustrating pharmacological intervention. The reversibility of non-covalent binding ensures that activation is dynamic and responsive to cellular cues.
Key Genes Involved in GO:0140677 molecular function activator activity
The following genes and proteins represent key molecular function activators or their targets, as supported by the verified literature.
| Gene | Major Role | Research Relevance |
|---|---|---|
| METTL3 | RNA methyltransferase; activation essential for exercise benefits | Diabetic cardiomyopathy |
| STAT5 | Transcription factor activated by engineered viral protein | T cell immunotherapy |
| CISD2 | Target of hesperetin; regulates senescence | Skin aging |
| SIRT1 | Deacetylase activated by small molecules | Metabolic and aging research |
| Proteasome 20S | Proteolytic complex activated by PA28 and others | Protein degradation |
| ARF (Auxin Response Factor) | Plant transcription factor regulated by auxin | Plant development |
| uPA/uPAR | Plasminogen activation system | Kidney disease |
| Transcriptional activators (e.g., p300) | Enhance transcription via coactivator recruitment | Gene regulation |
| Cofactors (e.g., Mediator) | Bridge activators and RNA polymerase II | Transcription |
| Chaperones (e.g., Hsp70) | Assist protein folding; can activate clients | Proteostasis |
| GTPases (e.g., Ras) | Activated by GEFs (Guanine nucleotide exchange factors) | Signaling |
| Kinases (e.g., Akt) | Activated by phosphorylation or allosteric binders | Cell survival |
| Nuclear receptors (e.g., ER) | Activated by ligand binding | Endocrinology |
| Complement factors | Activated in kidney disease | Nephrology |
| Auxin receptors (TIR1) | Activate ARF transcription factors | Plant biology |
How Is molecular function activator activity Regulated?
Molecular function activator activity is regulated at multiple levels. Activator abundance can be controlled by transcription, translation, and degradation. Post-translational modifications such as phosphorylation can modulate activator binding affinity. For example, the interaction between an engineered viral protein and STAT5 is likely regulated by cellular signaling. Small molecules can act as exogenous regulators, as seen with amiloride reducing complement activation. Additionally, competitive inhibitors can block activator binding, providing a layer of control.
molecular function activator activity and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| METTL3 | Diabetic cardiomyopathy | Cardiomyocyte-specific knockout mice |
| CISD2 | Skin aging | Keratinocyte overexpression and knockout |
| STAT5 | T cell suppression in cancer | Jurkat or primary T cells with engineered activator |
| uPA/uPAR | Glomerular proteinuria | Podocyte-specific knockout or knock-in |
| SIRT1 | Metabolic syndrome | Liver-specific transgenic mice |
Metabolic and cardiovascular disease
METTL3 activation is essential for exercise benefits in diabetic cardiomyopathy, suggesting that impaired activator function contributes to disease progression. Modulating METTL3 activity could be a therapeutic strategy.
Kidney disease
In glomerular proteinuria, urokinase/plasminogen-driven complement activation is reduced by amiloride, highlighting the role of activator-inhibitor balance in kidney pathology.
Aging and senescence
Hesperetin activates CISD2 to attenuate senescence in human keratinocytes and rejuvenates aged skin in mice, linking activator function to aging. Sirtuin activators are also studied for age-related diseases.
Cancer and immunotherapy
Engineered viral protein activation of STAT5 prevents T cell suppression, enhancing anti-tumor immunity. Dysregulated transcriptional activators can drive oncogenesis.
From molecular function activator activity-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of activator cause disease? | Knockout mice or cells (e.g., METTL3 KO) |
| Does a point mutation alter activator binding? | Point-mutation knock-in (e.g., STAT5 mutant) |
| Can activator be tagged for imaging? | Tagged knock-in (e.g., GFP-STAT5) |
| Does overexpression enhance activity? | Overexpression cell lines (e.g., CISD2) |
| Can small molecules activate target? | Pharmacological activation assays (e.g., sirtuin) |
| Can CRISPR screen identify novel activators? | Genome-wide CRISPR activation screen |
How to Study the molecular function activator activity Process
| Method | What It Measures | Typical Application |
|---|---|---|
| CRISPRa screen | Activation of gene expression | Identify novel activators |
| Co-IP | Protein-protein interaction | Confirm activator-target binding |
| SPR | Binding affinity and kinetics | Quantify non-covalent binding |
| Reporter assay | Target activity | Measure activation in cells |
| Cryo-EM | 3D structure | Visualize conformational changes |
| RNA-seq | Transcriptional changes | Downstream effects of activation |
| Proteomics | Protein abundance and modifications | Global effects of activator |
| Flow cytometry | Cell phenotype | Immune cell activation |
CRISPR activation screens
Genome-wide CRISPR activation (CRISPRa) screens can identify activators that enhance a phenotype of interest. This approach has been used to discover transcriptional activators in human cells.
Biochemical binding assays
Co-immunoprecipitation, pull-down, and surface plasmon resonance (SPR) can measure non-covalent binding between activator and target. These methods are essential to confirm direct interaction.
Functional activity assays
Enzymatic or reporter assays measure the increase in target activity. For example, sirtuin deacetylase activity can be monitored with fluorogenic substrates.
Structural biology
Cryo-EM and X-ray crystallography reveal conformational changes induced by activator binding, as seen for proteasome activators.
How CRISPR Can Be Used to Study GO:0140677 molecular function activator activity
Knockout
CRISPR knockout of an activator gene can abolish its function, revealing its necessity. For example, METTL3 knockout impairs exercise benefits in diabetic cardiomyopathy.
Point Mutation
Introducing point mutations in the activator or its binding interface can dissect specific residues required for non-covalent activation. This is useful for STAT5 activation studies.
Knock-in
Knock-in of tagged or reporter versions of activators allows real-time tracking and validation of expression. Tagged STAT5 knock-in can monitor activation dynamics.
Overexpression
Overexpression of an activator can enhance target activity and phenotype. For instance, CISD2 overexpression mimics hesperetin effects.
How EDITGENE Supports molecular function activator activity Research
Researchers studying molecular function activator activity-related genes often need to determine whether a candidate gene is causally involved in a phenotype, how its activation is regulated, and whether it can be targeted therapeutically. EDITGENE provides end-to-end CRISPR services to address these questions with precision and reproducibility.
Contact EDITGENE today to design your custom CRISPR model for molecular function activator activity research.
Frequently Asked Questions About molecular function activator activity
What is molecular function activator activity?
It is a GO molecular function (GO:0140677) where a regulator non-covalently binds to a target and increases its activity without modifying it.
What genes are involved in molecular function activator activity?
Genes include METTL3, STAT5, CISD2, SIRT1, and many transcriptional activators [1,3,5,8].
How does a molecular function activator work?
It binds to its target, often inducing a conformational change that enhances activity, as seen with sirtuin activators.
What diseases are linked to activator dysfunction?
Diabetic cardiomyopathy, kidney disease, aging, and cancer [1,5,7,8].
Can CRISPR be used to study activator activity?
Yes, knockout, knock-in, and CRISPRa screens are powerful tools.
What is the difference between an activator and an inhibitor?
Activators increase target activity, while inhibitors decrease it; both act non-covalently.
Are there small-molecule activators?
Yes, examples include resveratrol for sirtuins and hesperetin for CISD2 [3,5].
How can I measure activator activity?
Use binding assays, reporter assays, and functional readouts like deacetylation [3,4].
What is a CRISPR activation screen?
A method to overexpress genes genome-wide to identify activators of a phenotype.
Why is molecular function activator activity important?
It regulates key processes and offers therapeutic targets for many diseases [1,8].
Conclusion
Molecular function activator activity (GO:0140677) is a fundamental regulatory mechanism that controls protein function through non-covalent binding. Its roles span transcription, proteolysis, metabolism, and immunity, with direct implications for diseases such as diabetic cardiomyopathy, kidney disease, and cancer. Leveraging CRISPR technologies and biochemical assays, researchers can dissect activator mechanisms and develop targeted therapies. EDITGENE offers comprehensive services to support these investigations.
References
- 1. Wang C et al.. 2025. METTL3 Is Essential for Exercise Benefits in Diabetic Cardiomyopathy.. Circulation 152(5):327-345 PMID: 40357551
- 2. Alerasool N et al.. 2022. Identification and functional characterization of transcriptional activators in human cells.. Mol Cell 82(3):677-695.e7 PMID: 35016035
- 3. Alcaín FJ et al.. 2009. Sirtuin activators.. Expert Opin Ther Pat 19(4):403-14 PMID: 19441923
- 4. Stadtmueller BM et al.. 2011. Proteasome activators.. Mol Cell 41(1):8-19 PMID: 21211719
- 5. Shen ZQ et al.. 2024. Hesperetin activates CISD2 to attenuate senescence in human keratinocytes from an older person and rejuvenates naturally aged skin in mice.. J Biomed Sci 31(1):15 PMID: 38263133
- 6. Chandler JW. 2016. Auxin response factors.. Plant Cell Environ 39(5):1014-28 PMID: 26487015
- 7. Isaksson GL et al.. 2024. Amiloride Reduces Urokinase/Plasminogen-Driven Intratubular Complement Activation in Glomerular Proteinuria.. J Am Soc Nephrol 35(4):410-425 PMID: 38254266
- 8. Zheng Y et al.. 2025. An engineered viral protein activates STAT5 to prevent T cell suppression.. Sci Immunol 10(107):eadn9633 PMID: 40408430
